IL1B and type 2 diabetes mellitus: For instance, several studies have demonstrated that treatment with neutralizing IL-1β antibody or blockage of IL-1β signaling improved glycaemic control in diet-induced obese mice and insulin sensitivity in patients with T2D [173–176].